Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 206Neoplasms 191Carcinoma, Non-Small-Cell Lung 91Colorectal Neoplasms 89Prostatic Neoplasms 78Lung Neoplasms 73Multiple Myeloma 49Head and Neck Neoplasms 47Melanoma 46Pancreatic Neoplasms 43Neoplasm Metastasis 42Leukemia, Myeloid, Acute 41Carcinoma, Hepatocellular 40Recurrence 34Brain Neoplasms 34Squamous Cell Carcinoma of Head and Neck 33Ovarian Neoplasms 31Glioblastoma 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 28Glioma 27Uterine Cervical Neoplasms 26Sarcoma 26Lymphoma, Non-Hodgkin 26Lymphoma 26Stomach Neoplasms 25Lymphoma, Follicular 24Carcinoma, Renal Cell 24Esophageal Neoplasms 22Colonic Neoplasms 22Rectal Neoplasms 21

Interventions

zanidatamab 1tislelizumab 1sitravatinib 1pamiparib 1lenvatinib 1Temozolomide 1HMPL-013 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Malignancies × 90 days × Clear all
NCT04164199 2026-06-03

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

BeOne Medicines

Phase 3 Completed
404 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡